InnoGene Co

InnoGene Co CROIC

The Cash Return on Invested Capital (CROIC) of InnoGene Co (344860.KQ) as of Oct 16, 2026 is 4.62 %. In the previous year, Cash Return on Invested Capital (CROIC) was 13.63 % — a change of -66.09% (lower).

CROIC

4.62 %

YoY

-66.09%

Last updated:

Cash Return on Invested Capital (CROIC) of InnoGene Co is 2024 4.62 % . Cash Return on Invested Capital (CROIC) of InnoGene Co was 2023 13.63 % . It decreases by -66.09% lower compared to the previous year.

The InnoGene Co CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-13.23 KRW
Jan 1, 2019
13.57 KRW
Jan 1, 2020
23.72 KRW
Jan 1, 2021
39.10 KRW
Jan 1, 2022
8.14 KRW
Jan 1, 2023
13.63 KRW
Jan 1, 2024
4.62 KRW
The InnoGene Co CROIC history
YEARCROICYoY
4.62 %-66.09%
13.63 %+67.34%
8.14 %-79.18%
39.10 %+64.88%
23.72 %+74.77%
13.57 %-202.57%
-13.23 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

InnoGene Co Stock analysis

What does InnoGene Co do? InnoGene Co Ltd is a company based in Seoul, South Korea, operating within the Consumer Staples sector and the Consumer products industry. The company has 77 employees and went public on April 27, 2020. Its website is http://www.innogene.com/. InnoGene focuses on research and development related to skin regeneration and anti-aging solutions, utilizing stem cell technology and fusion technology. The company develops and manufactures cosmetics aimed at skin regeneration and aging control. Additionally, InnoGene is involved in the manufacturing and distribution of medical devices. The company's primary activities revolve around creating products that address skin health and aging concerns, leveraging scientific research in stem cell applications. As a publicly traded entity, InnoGene operates under the ticker symbol 344860.KQ and is registered with the ISIN KR7344860002. The company's headquarters are located in Seoul, and it serves a market that values innovative skincare and medical device solutions. InnoGene's product portfolio includes both cosmetic and medical device offerings, targeting consumers interested in advanced skincare technologies. The company's operations are centered on research-driven development to enhance skin health and combat aging effects. InnoGene Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about InnoGene Co stock

Cash Return on Invested Capital (CROIC) of InnoGene Co is 4.62 % in 2024.

Cash Return on Invested Capital (CROIC) of InnoGene Co changed from 13.63 % to 4.62 %, representing a -66.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) InnoGene Co since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s InnoGene Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — InnoGene Co

All Key Metrics — InnoGene Co